New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir, a NS5A inhibitor, and asunaprevir, a NS3 inhibitor, among genotype 1b hepatitis C virus infected patients. Results showed that the 24-week regimen achieved an overall sustained virologic response 12 weeks after the end of treatment among treatment-naÔve, peginterferon/ribavirin non-responder and peginterferon/ribavirin ineligible/intolerant patients, including cirrhotic and non-cirrhotic patients. In the study the DCV+ASV regimen was generally well tolerated. These data will be presented this week at the 49th annual meeting of the European Association for the Study of the Liver The International Liver Congress in London, April 9-13. These data were part of the companyís recent DCV and ASV new drug application submissions to the U.S. Food and Drug Administration, and helped support the validated marketing authorization application to the European Medicines Agency for the use of DCV in combination with other agents for the treatment of adults with HCV with compensated liver disease, including genotypes 1, 2, 3, and 4. These data are comparable to a similar Phase III study of this regimen in Japanese patients, which led to the submission of a New Drug Application with Japanís Pharmaceutical and Medical Devices Agency.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
11:31 EDTBMYLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use